Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological diseases. The company's lead product candidate, LP352, is a small molecule that targets the G protein-coupled receptor 3 (GPR3) and is being developed for the treatment of Alzheimer's disease. Longboard is also developing a pipeline of other small molecule product candidates for the treatment of other neurological diseases, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.